Tag Archive for ‘clinical trials’
The role of precision immunotherapy in treating solid tumors is summarized.
An educational program developed jointly by the ACS CRP and the Society of Surgical Oncology provides surgeons with the tools they need to actively participate in clinical trials
The role of immunotherapy in the treatment of urologic cancers is summarized and the efficacy of novel immunotherapeutics, particularly checkpoint inhibitors, are described, which may hold promise for a wide variety of tumor types.
Gastric cancer is a significant cause of cancer morbidity and mortality in the U.S., with an estimated 26,370 new cases and 10,730 deaths in 2016.1 The incidence of gastric cancer is rising, particularly proximal tumors, and among young (< 40 years old) Caucasians, who have experienced a nearly 70 percent increase in the incidence of […]
The mission of the Dissemination and Implementation Committee—to provide surgeons with practice-changing results of the Alliance and other national clinical trial groups—is summarized.
Decision aids to enhance conversations with minority males entering prostate cancer treatment are described.
Strategies for enhancing junior investigator participation in Alliance programs are highlighted.
Improving rectal cancer outcomes through advocacy, education, and research: The OSTRiCh Consortium and the new NAPRC
Over the last three decades, there has been a significant shift in cancer care from the generalist to the specialist setting. This shift is especially true in surgical oncology, where surgeons specializing in the care of breast cancer, esophageal cancer, and pancreatic cancer have become the norm for many facilities treating cancer patients in the […]
The approach, aims, and eligibility criteria of the NRG Oncology TNT clinical trial are summarized.
This month’s column underscores the importance of clinical trial participation, in particular surgeons who have a demonstrated capability and knowledge in conducting research-related operations.
Pancreatic cancer is the fourth-most common cause of cancer-related death in the U.S. and is predicted to soon be the third-leading cause. Surgical resection with pancreatectomy has historically been viewed as offering the only chance for cure. However, achieving negative margins at surgery can be difficult, with positive surgical margins found in as many as […]
The aim and approach of the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction trial is the focus of this month’s column.
Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options
The uptake of neoadjuvant endocrine therapy in the U.S. has been slow according to the authors of this month’s column, even though this treatment can reduce the extent of breast surgery.
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results
The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.
This month’s column summarizes the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) platform and how it facilities definitive studies of adjuvant targeted therapies in biomarker-selected non-small cell lung cancer patients.
This column addresses the efficacy of combining existing approaches with active therapeutic combinations to treat cancers of the stomach and esophagus.
A clinical trial is exploring whether limited resection should replace lobectomy as the gold standard for treatment of early-stage lung cancer.
This article presents a case study involving an ethical dilemma in which a pharmaceutical company asks a physician to participate in a clinical trial and offers to pay the physician for enrolling patients in the study. The authors explore four options for resolving the dilemma: accept the offer and only reveal details relevant to informed consent, accept the offer and inform patients of the reimbursement arrangement, participate in the clinical trial without accepting reimbursement, and avoid participating in the clinical trial altogether.
Older adults are projected to comprise a significant portion of a surgeon’s patient population. However, current surgical oncology trials are not designed to allow for widespread generalizability to their practice. This column features insights into the gap between cancer trials and the real world and the potential role of Z901101 in stimulating future studies and polices to broaden the accrual of older adults and their surgeons in new oncology trials.
This column discusses how multimodality therapy, including surgical resection, now represents a potential route to long-term survival for a group of patients with so-called “borderline resectable” cancers.